tiprankstipranks
Advertisement
Advertisement
Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
PremiumThe FlyMonte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
3M ago
Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
Premium
The Fly
Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
4M ago
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
Premium
The Fly
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
4M ago
Monte Rosa Therapeutics Prices $300 Million Public Offering
PremiumCompany AnnouncementsMonte Rosa Therapeutics Prices $300 Million Public Offering
6M ago
Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00
Premium
The Fly
Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00
6M ago
Monte Rosa Therapeutics Ends Current ATM Equity Program
Premium
Company Announcements
Monte Rosa Therapeutics Ends Current ATM Equity Program
6M ago
Monte Rosa data position MRT-8102 ‘favorably,’ says LifeSci Capital
PremiumThe FlyMonte Rosa data position MRT-8102 ‘favorably,’ says LifeSci Capital
6M ago
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
Premium
The Fly
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
6M ago
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today
Premium
Market News
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100